Isecarosmab  (Synonyms: 艾司卡索单抗; M-6495)

Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a K_D value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life^[1][2][3].

VH-VH'

Humanized

Isecarosmab 结合 ADAMTS-5，但不结合 ADAMTS-1、ADAMTS-4 和 ADAMTS-15^[1]。
Isecarosmab (1-100 nM，5 天) 在受到促炎刺激的牛和 OA 人软骨外植体中降低 huARGS、exAGNxI 和 GAG 水平^[1]。
Isecarosmab (24-72 h) 阻断 ADAMTS-5 介导的 DCS TLR2 激活^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Isecarosmab (0.1-10 mg/kg，皮下注射，每三天一次) 减轻内侧半月板 (DMM) 切除小鼠的内侧软骨退化^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

2254082-79-4

液体

Colorless to light yellow

艾司卡索单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  VH-VH'

• [1]. Siebuhr AS, et al. The Anti-ADAMTS-5 Nanobody® M6495 Protects Cartilage Degradation Ex Vivo. Int J Mol Sci. 2020 Aug 20;21(17):5992.  [Content Brief]

  [2]. Sharma N, et al. Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors. Osteoarthritis Cartilage. 2020 May;28(5):658-668.  [Content Brief]

  [3]. C. Brenneis. Structural and symptomatic benefit of a half-live extended, systemically applied anti-ADAMTS-5 inhibitor (M6495). 2018. 26 (1), S299-S300.